Based on the main role of vascular endothelial growth factor (VEGF) in tumour angiogenesis and immunosuppression10, co-inhibition of VEGF and PD-1 signalling showed promising activity in melanoma, renal cell carcinoma, and some sarcoma subtypes11,12. This evidence concerns the gene VEGFA and melanoma.